Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Stock Holdings Increased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC raised its holdings in shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) by 2,064.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,008 shares of the company’s stock after buying an additional 2,869 shares during the period. Tower Research Capital LLC TRC’s holdings in Fusion Pharmaceuticals were worth $29,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Signaturefd LLC raised its holdings in Fusion Pharmaceuticals by 883.0% during the 4th quarter. Signaturefd LLC now owns 2,949 shares of the company’s stock worth $28,000 after buying an additional 2,649 shares during the period. New York State Common Retirement Fund purchased a new stake in shares of Fusion Pharmaceuticals in the 4th quarter valued at approximately $64,000. China Universal Asset Management Co. Ltd. acquired a new position in Fusion Pharmaceuticals in the 4th quarter worth approximately $80,000. abrdn plc acquired a new position in Fusion Pharmaceuticals in the 4th quarter worth approximately $209,000. Finally, NEOS Investment Management LLC grew its position in Fusion Pharmaceuticals by 76.9% during the 4th quarter. NEOS Investment Management LLC now owns 30,939 shares of the company’s stock worth $297,000 after purchasing an additional 13,446 shares in the last quarter. Institutional investors and hedge funds own 72.85% of the company’s stock.

Fusion Pharmaceuticals Stock Down 0.2 %

Fusion Pharmaceuticals stock traded down $0.04 during mid-day trading on Friday, hitting $21.45. 468,542 shares of the company’s stock were exchanged, compared to its average volume of 967,541. Fusion Pharmaceuticals Inc. has a 1-year low of $2.31 and a 1-year high of $21.58. The stock has a 50 day moving average of $17.92 and a two-hundred day moving average of $11.07. The company has a current ratio of 15.01, a quick ratio of 15.01 and a debt-to-equity ratio of 0.16. The stock has a market cap of $1.82 billion, a P/E ratio of -14.59 and a beta of -0.69.

Fusion Pharmaceuticals (NASDAQ:FUSN) last issued its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%. As a group, analysts anticipate that Fusion Pharmaceuticals Inc. will post -1.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on FUSN shares. SVB Leerink reiterated a “market perform” rating and set a $21.00 price target (up previously from $17.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Bloom Burton lowered shares of Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. TD Cowen restated a “hold” rating on shares of Fusion Pharmaceuticals in a report on Tuesday, April 16th. Jonestrading reiterated a “hold” rating on shares of Fusion Pharmaceuticals in a research note on Wednesday, March 20th. Finally, B. Riley lowered shares of Fusion Pharmaceuticals from a “buy” rating to a “neutral” rating and lifted their target price for the company from $13.00 to $23.00 in a research note on Wednesday, March 20th. Thirteen research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $20.25.

Fusion Pharmaceuticals Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.